Premium
Effect of dexamethasone intravitreal implant in the treatment of noninfectious uveitis
Author(s) -
Frère A.,
Janssens X.,
Makhoul D.,
Judice L.,
Postelmans L.,
Lefèbvre P.,
Caspers L.,
Willermain F.
Publication year - 2015
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2015.0440
Subject(s) - medicine , dexamethasone , intraocular pressure , uveitis , visual acuity , ophthalmology , implant , surgery
Purpose To investigate the effect of dexamethasone intravitreal implant (Ozurdex; Allergan, Inc) in noninfectious uveitis. Methods Charts of patients with noninfectious uveitis treated by dexamethasone intravitreal implants were reviewed in a retrospective study. Uveitis etiologies, treatment indications, visual acuity, central retinal thickness measured by optical coherence tomography, intraocular pressure and number of injections were collected. Parameters were analyzed before injection (29 ± 6 days), after 5–6 weeks (49 ± 10 days) (short follow‐up) and 4–5 months (134 ± 2 days) (long follow‐up) post Ozurdex injection. Results We included 14 patients (20 eyes, 26 implants injections). Before injections, mean visual acuity was 0.5 ± 0.5 log MAR and improved to 0.3 ± 0.4 log MAR at short time follow‐up and to 0.3 ± 0.5 log MAR at long time follow‐up. Macular thickness has decreased by 101 ± 126 µm at short time follow‐up and 83 ± 162 µm at long time follow‐up. Mean intraocular pressure was 16 ± 5 mmHg before injections, 17 ± 6 mmHg at short time follow‐up and 15 ± 3 mmHg at long time follow‐up. Conclusions In noninfectious uveitis, dexamethasone implant can improve visual acuity and decrease macular thickness without significant increase of intraocular pressure. Although the effect seems limited in time.